The drug maker stops another late-stage clinical trial, representing yet another failure in efforts to treat the disease.
By ANDREW POLLACK, NY Times: Business
Tue, 08/17/2010 - 8:36am
The drug maker stops another late-stage clinical trial, representing yet another failure in efforts to treat the disease.